Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HGS, GSK report SLE drug study results
The BLISS-52 study, one of two pivotal Phase 3 trials, was designed to evaluate the efficacy and safety of belimumab plus standard of care, versus placebo plus standard
The BLISS-52 study, one of two pivotal Phase 3 trials, was designed to evaluate the efficacy and safety of belimumab plus standard of care, versus placebo plus standard
The study showed that women who were treated with a combination of Avastin and chemotherapy (carboplatin and gemcitabine), followed by continued use of Avastin alone until disease progression,
The study is in addition to the companies’ joint Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD. The RENAISSANCE Program is designed to support
Viibryd is a novel drug for the treatment of adults with major depressive disorder (MDD). ScinoPharm president and CEO Jo Shen said beginning from process research through timely
SMSH is the parent company of American Health, a provider of Medicare Advantage services to over 40,000 dual and non-dual eligible members in Puerto Rico. Triple-S Management president
Earlier Ansaris and Ono Pharmaceutical have entered into drug discovery collaboration for the identification of a kinase-related compound for the treatment of cancer, inflammatory and autoimmune diseases. Ono
The company has signed a leasing agreement in the Coyol Free Trade Zone and Business Park in Alajuela, Costa Rica, and plans to invest more than $4m in
Micocin is a targeted solution (it can recognize, target and inhibit bacterial growth) that can reduce risk and food product recall by controlling the growth of Listeria in
Doll has over 26 years of pharmaceutical industry experience in commercial operations, including his tenure as Impax Laboratories’ executive vice president for commercial operations from 2006 to 2008.
According to AstraZeneca, an early efficacy review by the Independent Data Monitoring Committee (IDMC) revealed that zibotentan monotherapy was unlikely to meet primary efficacy endpoints of progression free